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Jie Zuo1, Daniel S Brewer2, Volker M Arlt3, Colin S Cooper4 and David H Phillips3*Abstract
Background: Gene expression changes induced by carcinogens may identify differences in molecular function
between target and non-target organs. Target organs for benzo[a]pyrene (BaP) carcinogenicity in mice (lung, spleen
and forestomach) and three non-target organs (liver, colon and glandular stomach) were investigated for DNA
adducts by 32P-postlabelling, for gene expression changes by cDNA microarray and for miRNA expression changes
by miRNA microarray after exposure of animals to BaP.
Results: BaP-DNA adduct formation occurred in all six organs at levels that did not distinguish between target and
non-target. cDNA microarray analysis showed a variety of genes modulated significantly by BaP in the six organs and
the overall gene expression patterns were tissue specific. Gene ontology analysis also revealed that BaP-induced
bioactivities were tissue specific; eight genes (Tubb5, Fos, Cdh1, Cyp1a1, Apc, Myc, Ctnnb1 and Cav) showed significant
expression difference between three target and three non-target organs. Additionally, several gene expression changes,
such as in Trp53 activation and Stat3 activity suggested some similarities in molecular mechanisms in two target organs
(lung and spleen), which were not found in the other four organs. Changes in miRNA expression were generally tissue
specific, involving, in total, 21/54 miRNAs significantly up- or down-regulated.
Conclusions: Altogether, these findings showed that DNA adduct levels and early gene expression changes did not
fully distinguish target from non-target organs. However, mechanisms related to early changes in p53, Stat3 and Wnt/
β-catenin pathways may play roles in defining BaP organotropism.
Keywords: Carcinogenicity, Organotropism, Benzo[a]pyrene, DNA adducts, Gene expression, Microarray, miRNABackground
DNA adduct formation is an early critical event in the
process of carcinogenesis by which many chemical carcin-
ogens exert their biological effects. With few exceptions,
however, carcinogens form DNA adducts in many tissues,
leading to the view that adducts are necessary, but not suf-
ficient, for carcinogenesis. Thus, although there are linear
relationships between dose, adduct levels in target organs
and tumour incidence [1], it may be difficult to identify
which organs are targets for carcinogenicity by an agent
purely from a consideration of the levels and persistence
of DNA damage. Several studies using transgenic mice* Correspondence: david.phillips@kcl.ac.uk
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unless otherwise stated.demonstrate that there is also a lack of correlation be-
tween carcinogen-induced increases in mutation fre-
quency and target organ specificity [2-4]. These findings
suggest the importance of events subsequent to DNA
damage and mutation in determining organotropism and
inter-species differences of carcinogens.
There have been reports of early gene expression
changes in animal tissues following exposure to carcino-
gens or toxins, but thus far most studies have been limited
to examinations of one target tissue with, usually, one
non-target tissue [5-9]. No study has yet attempted to
compare several target and non-target tissues in order to
define the critical events subsequent to DNA damage and
mutation that may determine carcinogen organotropism.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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carcinogen-induced changes in gene expression or miRNA
expression may distinguish target organs from non-target
ones. Balb/c mice were treated with multiple carcinogenic
doses of benzo[a]pyrene (BaP), after which DNA adduct
levels and gene and miRNA expression changes were mea-
sured in three target organs (lung, spleen and forestomach)
and three non-target organs (liver, colon and glandular
stomach). We found some similar expression changes in at
least some of the target organs, but that the majority of the
early gene expression changes were tissue specific, as were
some of the biological processes related to the modulated
genes. Nevertheless, the results shed new light on the com-
plexity of the mechanism of BaP carcinogenicity and iden-
tify some responses that may determine the carcinogen’s
organotropism.Results
DNA adducts
32P-Postlabelling analysis of DNA from all six organs of
BaP-treated mice (Experiment 1) showed a single adduct
spot on TLC (Figure 1A). The radioactivity in this spot co-
chromatographed with that produced by the standard benzo
[a]pyrene diol-epoxide (BPDE)-modified DNA [10]. TLC
plates of DNA from control animals were devoid of adducts
(Figure 1A). Adduct levels in the six organs are shown in
Figure 1B. For each organ, levels were not significantly dif-
ferent between males and females (Student’s t-test, p > 0.05).
They were higher in mice treated with ten daily doses than
in those treated with five: 50% higher in lung, 65% higher in
spleen, 138% higher in forestomach, 41% higher in liver,
177% higher in colon and 80% higher in glandular stomach.
The increases from five to ten doses were significant (p <
0.05) for all organs except lung. Differences in DNA adduct
levels among the organs (1-way ANOVA) or between pairs
of target and non-target organs (Tukey-Kramer test) were
not significant (p > 0.05). Thus there was no significant dis-
tinction between target and non-target organs for DNA ad-
duct formation.Gene expression profiles
By comparing pooled expression profiles from all BaP-
treated samples from Experiment 2 (males and females at 3
different BaP doses) with corn oil-treated controls for each
organ, we identified 791 genes in lung, 956 in spleen, 535 in
forestomach, 309 in liver, 357 in colon and 939 in glandular
stomach as significantly modulated by BaP (Welch’s t-test,
p < 0.05), combining to a total of 2741 genes (Additional file
1: Table S1). This gene list was used for the subsequent clus-
ter and functional analyses. Expression profiles were pooled
in order to increase the power of the test and to reduce the
weight of any one sample reducing the effect of outliers.Principal component analysis (PCA) and hierarchical
cluster analysis (HCA)
PCA was used to analyse the expression profile of genes
modulated significantly by BaP in at least one organ (2741
unique genes). Separate or nearly separate clusters were
observed for lung, spleen and liver (Figure 2A). In con-
trast, there was overlap for the conditions in forestomach,
colon and glandular stomach. The expression profiles of
modulated genes uniquely define two of the target organs,
lung and spleen. It is clear that the variations due to tissue
differences are greater than variations due to BaP
treatment.
In hierarchical clustering, the six profiles (3 doses × 2
genders) for each organ clustered together (Figure 2B).
There was a closer similarity between the expression
patterns of forestomach (target) and glandular stomach
(non-target) than between any of the other organs.
Again, the target organs lung and spleen clustered
separately from the other organs. The corn-oil control
samples clustered with the BaP-treated samples from
the same organ again indicating that differences in ex-
pression profiles between organs were greater that the
change induced by BaP.
BaP-modulated gene expression in individual conditions
We identified 958 genes in lung, 1085 in spleen, 645 in for-
estomach, 523 in liver, 406 in colon and 1104 in glandular
stomach that were significantly differentially modulated
between at least one of the six conditions (3 doses × 2 gen-
ders) and corn oil-treated control samples (Welch’s t-test;
p < 0.05). This represented 2770 different genes in total, of
which 1906 genes are also among the 2741 genes identified
by the pooling profiles method. To identify a consistent re-
sponse we also considered genes significantly altered in at
least three out of six conditions, for each tissue. There were
85 in lung, 108 in spleen, 97 in forestomach, 34 in liver, 25
in colon and 128 in glandular stomach (Representative
genes are shown in Table 1; see Additional file 1: Table S2
for the full list). Using these criteria, only one gene Hspa8
was found to be up-regulated in all six organs. Hba-a1 was
down-regulated in five organs.
The dose and gender effects on gene expression were in-
vestigated with 2-way ANOVA for each of the six organs.
We did not find any clear dose- or gender-dependent ex-
pression in any of the organs.
Target versus non-target gene comparisons
When comparing the genes modulated by BaP at three or
more exposure conditions, no gene was significantly modu-
lated in all target organs but not in any non-target organ,
or vice versa. Actb, Pdia3, Rpl18, Rps5 and Tmed5 were
identified to be up-regulated by BaP in comparison with
corn oil-treated controls in two out of three target organs
and in none of the non-target organs, whilst three genes
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Figure 1 BaP–DNA adduct formation in 6 Balb/c mouse organs. The mice received 5 or 10 daily doses of 125 mg/kg b.wt/day BaP, or corn
oil (control). (A) Autoradiographic profiles of DNA adducts obtained by TLC-32P-postlabelling. (B) Quantitative analysis of DNA adducts in mouse
organs. Values represent the mean ± SD (n = 3). RAL; relative adduct labelling, adducts/108 nucleotides. Differences between males and females
were not significant (p > 0.05). Differences between 5 and 10 days were significant (p < 0.05) except for lung (p = 0.06).
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http://www.biomedcentral.com/1471-2164/15/880were found to be down-regulated (Giyd2, Hbb-y, Pip5k1c).
Rpl17 was found to be up-regulated in two out of three
non-target organs and in none of the target organs. Tubb5
was found to be down-regulated in spleen and forestomach(two target organs) and up-regulated in the colon (one of
the non-target organs).
Examining the results of the differential analysis per-
formed on samples pooled by organ it was found that 25
(B)
lung (T)
spleen (T)
liver (NT)
colon (NT)
forestomach (T)
glandular stomach (NT)
(A)
Figure 2 Principal component analysis (PCA) and hierarchical cluster analysis (HCA). (A) PCA of 2791 genes modulated significantly by BaP
across 6 mouse organs. The first and second components were used (75.31% of total variances). The 8 hybridisation conditions in each of the 6
organs were grouped by gender and BaP dose (males or females, BaP dose of 125, 250 or 375 mg/kg b.wt/day and corn oil). T indicates target
organs and NT non-target organs. (B) HCA of 2741 genes modulated significantly by BaP across 6 mouse organs. The 48 hybridisation conditions
were clustered unsupervised. The results show tissue-specific expression patterns, especially in 2 target organs (lung and spleen). dose 1-corn oil,
dose 2-BaP 125 mg/kg b.wt/day, dose 3-BaP 250 mg/kg b.wt/day, dose 4-BaP 375 mg/kg b.wt/day. LU-lung, SP-spleen, FS-forestomach, LI-liver,
CO-colon, GS-glandular stomach.
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the same direction for either all target organs or all non-
target organs (Table 2; Welch’s t-test, p < 0.05). Of these,
genes Actg1, Crk and Dnajc3, and clones H3098D07 and
H3068A11 were found to be up-regulated in all target
organs and down-regulated or not modulated in all non-
target organs. Psmd2 was down-regulated in target
organs only and Pfpl was up-regulated in non-target or-
gans only. Sdccag1 was up-regulated in all organs and
Hspa5 in five organs. Hbb-y and Hba-a1 were generally
down-regulated in all organs.Functional analysis of the modulated genes
We applied various bioinformatics approaches using the
BaP-induced genes (see Additional file 1: Table S1) to
identify which biological activities are modulated in BaP
tumourigenesis. Firstly, in gene ontology (GO) analysis,
the comparison of biological processes revealed consid-
erable variation between the six organs (Additional
file 1: Table S3). A few biological processes were common
to all organs, and most of these were related to basic
physiological activities like metabolic (GO:0008152), bio-
synthetic (GO:0009058) and macromolecule biosynthetic
Table 1 Genes significantly modulated by BaP in individual organs (Welch’s t-test, p < 0.05) for at least three
conditions
Probe Symbol Gene name EntrezID M1* M2 M3 F1 F2 F3
Lung (target)
H3018D10 Actb Actin, beta, cytoplasmic 11461 1.310 1.280 1.290 1.020 1.010 1.080
H3089D06 Cav Caveolae protein 1 12389 2.350 2.270 2.260 1.500 1.730 1.660
H3110F10 Ephx1 Epoxide hydrolase 1, microsomal 13849 1.424 1.696 1.658 2.220 2.382 2.910
H3114C04 Giyd2 Giy-yig domain containing 2 75764 0.530 0.800 0.610 0.430 0.410 0.600
H3125H11 Hba-a1 Hemoglobin alpha, adult chain 1 15122 0.597 0.687 0.487 0.502 0.442 0.580
H3117D02 Hbb-y Hemoglobin y, beta-like embryonic chain 15135 0.445 0.732 0.356 0.369 0.217 0.405
H3139E01 Hspa8 Heat shock protein 8 15481 1.687 2.068 1.994 2.060 1.954 1.625
H3097B08 Pdia3 Protein disulfide isomerase associated 3 14827 1.211 1.283 1.388 1.270 1.126 1.232
H3126C02 Rpl18 Ribosomal protein l18 19899 1.350 1.400 1.490 1.040 1.010 0.980
H3112G04 Rps5 Ribosomal protein s5 20103 1.310 1.290 1.350 0.970 0.860 1.000
H3068A11 Tmed5 Transmembrane emp24 protein transport domain containing 5 73130 1.270 1.310 1.330 1.320 1.120 1.270
Spleen (target)
H3077H03 Ccng1 Cyclin g1 12450 1.342 1.362 1.665 1.359 1.564
H3114C04 Giyd2 Giy-yig domain containing 2 75764 0.443 0.393 0.513 0.484 0.203 0.383
H3126A10 Hba-a1 Hemoglobin alpha, adult chain 1 15122 0.540 0.661 0.581 0.358 0.327 0.335
H3134E01 Hbb-y Hemoglobin y, beta-like embryonic chain 15135 0.813 0.742 0.495 0.542 0.334 0.564
H3051C06 Hspa5 Heat shock 70kd protein 5 14828 1.061 1.359 1.433 1.047 1.241 1.522
H3139E01 Hspa8 Heat shock protein 8 15481 1.297 1.540 1.567 1.937 1.784 1.705
H3097B08 Pdia3 Protein disulfide isomerase associated 3 14827 1.126 1.224 1.388 1.161 1.204 1.425
H3130D03 Pip5k1c Phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma 18717 0.330 0.340 0.420 0.640 0.470 0.530
H3139D02 Tubb5 Tubulin, beta 5 22154 0.649 0.650 0.716 0.744 0.619 0.725
Forestomach (target)
H3011E09 Actb Actin, beta, cytoplasmic 11461 1.210 1.860 1.930 1.670 1.520 1.950
H3089D06 Cav Caveolae protein 1 12389 0.570 0.630 0.570 0.910 0.700
H3126H01 Hba-a1 Hemoglobin alpha, adult chain 1 15122 0.210 0.240 0.150 0.510 0.470 0.300
H3051C06 Hspa5 Heat shock 70kd protein 5 14828 1.332 1.837 2.287 1.716 1.687 1.803
H3139E01 Hspa8 Heat shock protein 8 15481 1.570 2.382 2.752 1.674 1.956 2.153
H3130D03 Pip5k1c Phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma 18717 0.520 0.550 0.740 0.590 0.560 0.790
H3126C02 Rpl18 Ribosomal protein l18 19899 1.510 1.370 1.640 0.950 1.030 1.160
H3112G02 Rps5 Ribosomal protein s5 20103 1.320 1.270 1.440 1.040 1.050 1.360
H3080H08 Tmed5 Transmembrane emp24 protein transport domain containing 5 73130 0.660 0.690 0.720 0.610 0.580 0.530
H3018E11 Tubb5 Tubulin, beta 5 22154 0.588 0.624 0.576 1.117 1.115 1.098
Liver (non-target)
H3133B06 Ccnd2 Cyclin d2 12444 1.757 2.639 1.519 1.724 1.532 1.924
H3125H11 Hba-a1 Hemoglobin alpha, adult chain 1 15122 0.170 0.420 0.490 0.490 0.280 0.290
H3139E01 Hspa8 Heat shock protein 8 15481 0.935 1.592 1.354 1.870 2.606 2.456
H3129E07 Rpl17 Ribosomal protein l17 319195 1.130 1.320 1.200 1.220 1.370 2.050
Colon (non-target)
H3139E01 Hspa8 Heat shock protein 8 15481 1.397 1.493 1.559 1.240 1.577 2.110
H3139D02 Tubb5 Tubulin, beta 5 22154 1.951 2.106 2.216 1.318 1.717 1.749
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Table 1 Genes significantly modulated by BaP in individual organs (Welch’s t-test, p < 0.05) for at least three
conditions (Continued)
Glandular stomach (non-target)
H3089D06 Cav Caveolae protein 1 12389 2.140 1.530 1.300
H3126H01 Hba-a1 Hemoglobin alpha, adult chain 1 15122 0.610 0.340 0.310 0.310 0.250 0.240
H3051C06 Hspa5 Heat shock 70kd protein 5 14828 1.316 1.780 1.294 1.253 1.661 1.165
H3029C06 Hspa8 Heat shock protein 8 15481 1.242 1.303 1.046 1.568 1.480 1.266
H3029F12 Rpl17 Ribosomal protein l17 319195 1.340 1.350 1.020 1.400 1.400 2.130
*Columns M1, M2, M3, F1, F2 and F3 show the relative fold-change values in 6 exposure conditions (M1-male 125, M2-male 250, M3-male 375, F1-female 125,
F2-female 250 and F3-female 375 mg/kg b.wt/day. Expression ratios in bold text mean being significant (p < 0.05) by Welch’s t-test. The genes shown in bold text
were subsequently validated by Taqman gene expression assay.
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http://www.biomedcentral.com/1471-2164/15/880(GO:0009059) processes. Conversely, a number of pro-
cesses showed tissue specificity, especially some cancer-
associated processes, for example, response to oxidative
stress in lung (six associated genes: Dhcr24, Gpx3, Sod1,
H47, Mtf1 and Prdx6) and cell growth in glandular stom-
ach (11 genes: Ube2e3, Alox12, Bcar1, Lepre1, Socs7, Sfn,
Shc1, Esr1, Ppp2ca, Crim1 and Yeats4). Comparisons be-
tween organs suggested that processes including transla-
tional initiation (GO:0006413), polyamine metabolic
process (GO:0006595), protein-RNA complex assembly
(GO:0022618) and regulation of protein metabolic process
(GO:0051246) represented target organ-specific functions
while gas transport (GO:0015669) was the only process
common to all the non-target organs. As we were asses-
sing the effects of BaP treatment we also examined func-
tions known to be involved in response to other external
stimuli, such as response to stress (GO:0006950), to DNA
damage stimulus (GO:0006974) and to oxidative stress
(GO:0006979). We found that these appeared to be differ-
ent in different organs, but do not fully distinguish target
from non-target organs (although most do occur in two
target organs). Other interesting activities such as DNA
packaging (GO:0006323), apoptosis (GO:0006915) and
cell proliferation (GO:0008283) were connected to cell
cycle regulatory activities. Interestingly, these biological
processes are also mainly altered in two target organs (e.
g. cell cycle and cell proliferation).
Secondly, approximately half of the BaP-modulated
genes in each organ were associated with regulatory or
metabolic pathways. Over 90% of the pathways were
found in more than one organ but most were common
to two or three organs only. A few pathways, including
cell cycle (genes including Cdkn2A, Ccng1, Pcna),
MAPK signalling, Wnt signalling (e.g. Apc, Src, Ccnd2,
Cdh1) and Jak-SAT signalling (Stat3), were modulated in
all six organs (Additional file 1: Table S4), although dif-
ferent genes were found to be modulated in each case.
For example, only Ccnd2 expression in the Wnt signal-
ling pathway was altered in all six organs. No pathway
activated by BaP distinguished all three target organs
from all three non-target organs.Thirdly, the interactive relationships among BaP-
modulated genes in each organ were investigated by gene
association network analysis using Ingenuity Pathway
Analysis (IPA). Over 50% of the significantly modulated
genes were present in networks. Networks commonly
have one or more core (or ‘hub’) gene that links to many
others within the network. NFκb in network 3 of lung
(Figure 3), for example, can be regulated by 10 genes
(Ecsit, Gpam, Ddost, Cops3, Birc4, Otud7b, Nedd4, Ube2,
Btrc and Rnf7) and it may regulate three others (Fuca1,
Cyb5r3 and Ccnd2). Other core genes including Erbb2,
Ctnnb1, Fos, Myc, Trp53, TNF, Stat3, H-ras, Hspa8 and
Mapk are associated with networks that had significantly
modulated genes. Of these, Fos and Hspa8 were them-
selves modulated. We did not find any network functions
that distinguished the target from the non-target organs.
Instead, cancer, cell cycle, protein synthesis and post-
translation modification were network functions common
to all six organs.
Taqman gene expression validation
The expression of 21 genes was measured by real-time
PCR (RT-PCR). These were selected because they were dif-
ferentially modulated by BaP between target and non-target
organs, differentially modulated in most organs, core net-
work genes or part of important pathways found to be
modulated in the functional analyses. Ephx1 [11,12],
Cyp1a1 [13,14] and Trp53 [15] were chosen as they have
previously been highlighted as important in BaP modula-
tion. Table 3 shows the expression changes of these 21
genes, of which 11 genes modulated by BaP represent tran-
scriptional differences between target organs and non-
target organs Trp53 and Pcna were down-regulated in two
target organs (lung and spleen); Cdh1, Ctnnb1 and Apc
were down-regulated in non-target organs (Ctnnb1 and
Apc in colon and glandular stomach, Cdh1 in all three non-
target organs); and Src was up-regulated in two target or-
gans (lung and spleen) (Table 3; Full results in Additional
file 1: Table S5). Additionally, Ccng1, Ephx1, Cyp1a1, Stat3
and Hspa8 were consistently up-regulated in the six organs.
Looking at differences in expression between BaP-treated
Table 2 Genes found to be significantly differentially expressed (Welch t-test p < 0.05) in the same direction for all
target organs or all non-target organs
Average ratio of BaP-treated
samples to oil treated control
Clone ID Symbol Gene name EntrezID Genbank LU SP FS LI CO GS
H3098H09 2310016E02Rik Riken cdna 2310016e02 gene 67695 BG071432 1.44 1.19 2.19 1.31 0.65 -
H3114E08 Actg1 Actin, gamma, cytoplasmic 1 11465 BG072752 1.20 1.17 1.27 - - -
H3134D01 AI461788 BG074374 1.53 1.28 1.41 2.02 - -
H3083A04 Crk V-crk sarcoma virus CT10 oncogene homolog (avian) 12928 BG069956 1.19 1.11 1.24 - - -
H3094A04 Dnajc3 DnaJ (Hsp40) homolog, subfamily C, member 3 100037258 BG071035 1.20 1.26 1.42 - - 0.90
H3134F05 Gstm1 Glutathione S-transferase, mu 1 14862 BG074397 2.29 1.43 1.46 2.26 - -
H3125H07 Hba-a1 Hemoglobin alpha, adult chain 1 15122 BG073608 0.59 0.54 0.57 0.26 - 0.42
H3125H08 Hba-a1 Hemoglobin alpha, adult chain 1 15122 CK334953 0.58 0.70 - 0.32 0.95 0.50
H3125H11 Hba-a1 Hemoglobin alpha, adult chain 1 15122 BG073610 0.54 0.77 0.40 0.35 - 0.37
H3126G09 Hba-a1 Hemoglobin alpha, adult chain 1 15122 CK334957 0.55 0.42 0.33 0.35 - 0.35
H3126H01 Hba-a1 Hemoglobin alpha, adult chain 1 15122 BG073679 0.58 0.44 0.28 0.25 2.02 0.32
H3140G04 Hba-a1 Hemoglobin alpha, adult chain 1 15122 BG074904 0.52 0.73 0.49 0.29 - 0.49
H3117D02 Hbb-y Hemoglobin Y, beta-like embryonic chain 15135 BG072990 0.39 - 0.45 0.23 0.95 0.44
H3134E01 Hbb-y Hemoglobin Y, beta-like embryonic chain 15135 CK335036 0.51 0.56 0.43 0.31 1.19 0.43
H3051C06 Hspa5 Heat shock protein 5 14828 CK334553 1.37 1.26 1.76 - 1.02 1.40
H3012A07 Hspa8 Heat shock protein 8 15481 BG063725 1.78 1.33 1.73 1.69 - -
H3119B04 Hspa8 Heat shock protein 8 15481 CK334899 1.79 1.36 1.62 1.46 0.93 -
H3139E01 Hspa8 Heat shock protein 8 15481 BG074803 1.89 1.61 2.04 1.70 0.75 -
H3058G09 Mod1 Malic enzyme 1, NADP (+)-dependent, cytosolic 17436 BG067842 1.74 1.37 1.39 1.57 - 1.26
H3012G01 Pfpl Pore forming protein-like 56093 CK334280 - - - 1.21 1.08 1.21
H3032C09 Psmd2 Proteasome (prosome, macropain) 26S subunit, non-ATPase,
2
21762 BG065537 0.87 0.89 0.84 - 1.50 -
H3082D02 Sdccag1 Serologically defined colon cancer antigen 1 71055 BG070064 1.59 1.58 1.53 1.52 1.05 1.46
H3106H07 Slco2a1 Solute carrier organic anion transporter family, member 2a1 24059 BG072114 1.46 1.22 1.32 - - 1.19
H3068A11 Tecpr1 Tectonin beta-propeller repeat containing 1 70381 BG068669 1.27 1.19 2.00 - 0.68 -
H3131D02 Tnk2 Tyrosine kinase, non-receptor, 2 51789 BG074141 - 0.85 - 0.78 0.71 0.56
H3098D07 1.12 1.10 1.31 - - -
H3114F08 1.11 1.29 1.10 - - 1.24
In the analysis samples were grouped by organ. All three doses are included. Ratios are only displayed for those organs where a significant difference was found.
LU = lung; SP = spleen; FS = forestomach; LI = liver; CO = colon; GS = glandular stomach.
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status, we found eight genes (Tubb5, Fos, Cdh1, Cyp1a1,
Apc, Myc, Ctnnb1 and Cav) to be modulated significantly
differently between target and non-target tissue (p < 0.05;
Figure 4). Even for these genes, a tissue might be more
consistent with the opposite group rather than with its
own. For example, for the top hit Tubb5, the gene with
the most significant difference, forestomach seems to be
more consistent with the non-target tissues.MicroRNA (miRNA) expression
The expressions of 54 mouse miRNAs on the micro-
array were first analysed using hierarchical clusteranalysis (Figure 5). The majority of changes of miRNA
expressions pattern were distinct for each of the six or-
gans and the target organs did not cluster separately
from the non-target organs. Instead, the results indicate
that the profiles of BaP-induced miRNA expression
changes in the six mouse organs are tissue specific.
The relative miRNA expression values of the BaP-treated
compared to control mice revealed the degree of modula-
tion of miRNAs expression by BaP. With a cut-off of 1.5-
fold, 41 out of 54 miRNAs displayed up-regulation or
down-regulation in one or more organ (Additional file 1:
Table S6). For instance, mmu-miR-290 was up-regulated in
all organs except forestomach; mmu-miR-465 was down-
regulated in lung, spleen and glandular stomach. Twenty
Figure 3 (See legend on next page.)
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Figure 3 Gene association network (GAN) 3 in lung. The network was generated with 791 BaP-significantly modulated genes by Ingenuity
Pathway Analysis (IPA). (A) shows 28 BaP-modulated genes. The gene-gene interactions reveal that NFκb can be regulated by 10 genes (Ecsit,
Gpam, Ddost, Cops3, Birc4, Otud7b, Nedd4, Ube2, Btrc and Rnf7) and it may regulate other 3 genes (Fuca1, Cyb5r3 and Ccnd2). It also shows that
core genes NFκb and Ube give central roles for the network functions protein synthesis and post-translational modification. Up-regulated genes
are shown in red; down-regulated genes are shown in green. (B) the descriptions of interactions and transcriptional factors.
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BaP-treated samples compared with control (p < 0.05, Stu-
dent’s t-test; Figure 6). The number of miRNAs significantly
altered in individual organs was as follows: 7 up, 3 down in
lung; 9 up, 1 down in spleen; 7 up, 5 down in forestomach;
8 up, 4 down in liver; 8 up, 0 down in colon; and 9 up, 0
down in glandular stomach (Figure 6). These analyses did
not identify any miRNA expression changes that were tar-
get organ-specific or non-target organ-specific.Table 3 Gene expression changes validation with RT-PCR
Symbol EntrezID Gene name
P53 related
Trp53 22059 Transformation related protein 5
Pcna 18538 Proliferating cell nuclear antige
Ccng1 12450 Cyclin G1
PAH metabolism
Ephx1 13849 Epoxide hydrolase 1, microsom
Cyp1a1 13076 Cytochrome P450, family 1, subfamily a, p
Wnt/β-catenin signalling
Cdh1 12550 Cadherin 1
Ctnnb1 12387 catenin
Apc 11789 Adenomatosis polyposis coli
Stat3 related
Stat 3 20848 Signal transducer and activator of trans
Erbb2 13866 v-erb-b2 erythroblastic leukemia viral oncoge
Src 20779 Rous sarcoma oncogene
Oncogene and tumour suppressor gene
Fos 14281 FBJ osteosarcoma oncogene
Myc 17869 Myelocytomatosis oncogene
Other genes
Cav 12389 Caveolin, caveolae protein 1
Tubb5 22154 Tubulin, beta 5
Cdkn2a 12578 Cyclin-dependent kinase inhibitor 2A
Ccnd2 12444 Cyclin D2
Hspa8 15481 Heat shock 70kD protein 8
Hspa5 14828 Heat shock 70kD protein 5
TNFα 21926 Tumor necrosis factor alpha
NFκb 18033 Nuclear factor of kappa light chain gene enha
The same RNA sample was measured 3 times independently for each exposure con
conditions in each organ was considered as being up- or down-regulated. ‘↑’ mean
means no data. LU, lung; SP, spleen, FS, forestomach; LI, liver; CO, colon; GS, glandulDiscussion
BaP is a well-studied multi-organ and multi-species geno-
toxic carcinogen. Its carcinogenic potency and organotrop-
ism in mice depends both on the route of administration
and on the dose [3,16-19]. Hakura et al. [3] treated mice
with 125 mg/kg b.wt/day of BaP by oral gavage for five con-
secutive days, which induced tumours in the forestomach,
spleen and lung. In the present study, we treated Balb/c
mice with BaP according to the same protocol. In addition,LU SP FS LI CO GS
3 ↓ ↓ F F F F
n ↓ ↓ − − − −
↑ ↑ ↑ ↑ ↑ ↑
al ↑ ↑ − ↑ ↑ ↑
olypeptide 1 ↑ ↑ ↑ ↑ ↑ ↑
− ↑ − ↓ ↓ ↓
− − − − ↓ ↓
− − − − ↓ ↓
cription 3 − ↑ ↑ ↑ ↑ ↑
ne homolog 2 ↑ F ↓ F ↓ ↓
↑ ↑ − F − −
↓ ↑ ↑ ↓ ↓ ↓
↓ − − ↑ − ↑
↑ ↑ ↓ ↑ − ↑
↓ ↓ − − − −
(P16) − ↑ ↑ ↑ F ↑
− ↑ ↓ ↑ ↑ −
↑ ↑ ↑ ↑ ↑ ↑
↑ − ↑ − ↑ ↑
↓ − F F ↑ F
ncer in B-cells 1 ↓ − F F ↓ F
dition, and the consistent changes with a cut-off 1.5 occurring in 3 or more
s up-regulation; ‘↓’ means down-regulation; ‘ – ’ means no change and ‘F’
ar stomach.
Figure 4 Boxplots of the eight genes found to be modulated significantly differently between target and non-target organs (p < 0.05;
Benjamin-Hochberg multiple testing correction applied). Expression values were normalised to the corn-oil control for each organ and
pooled according to target or non-target status. Each organ is identified by colour. The box indicates the median, upper and lower quartiles and
the whiskers are 1.5 times IQR (interquartile range; Q3-Q1) above/below the box.
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doses) in order to look for temporal changes in DNA ad-
duct levels and gene expression. We also used 2- and 3-fold
higher doses to investigate dose-related effects on gene
expression. Forestomach, spleen and lung, the three target
organs, were examined and we chose liver, colon and glan-
dular stomach as non-target organs for comparison.DNA adduct formation
As expected, BaP induced the same DNA adduct pattern,
consistent with metabolic activation to the 7,8-dihydrodiol
9,10-epoxide and covalent binding to the N2 position
of guanine [20], in all organs examined. The similar levels
of binding in males and females is consistent with the
carcinogenic equipotency of BaP in both sexes, but the
order of DNA adduct formation – spleen ≥ liver > lung >
glandular stomach ≥ colon > forestomach – did not correl-
ate with the susceptibility of the organs to BaP carcino-
genicity [3].Previous research has shown that mutation frequency in
organs of BaP-treated mice was in the order of colon > for-
estomach > spleen > glandular stomach > liver = lung, while
tumour incidence was in the order forestomach > spleen >
lung after treating male MutaMouse with 125 mg/kg b.wt/
day of BaP for 5 days by oral gavage [2,21]. There are other
examples of a lack of correlation between DNA adducts,
mutation frequency and tumour incidence in different or-
gans of carcinogen-treated mice [22,23], although some
level of correlation between mutation frequency and target
organs [24-27], or between adduct levels and target organs
[28], has been observed in some rodent studies.
While DNA adduct formation and mutation induction
are important initiating events in carcinogenesis, these
findings point to the possible role of subsequent events
in determining the organotropism of chemical carcino-
gens. Thus in the present study we analysed microarray
expression data from six organs of mice treated with
BaP to look for tissue-specific changes. In total, data
were collected from 144 hybridisations.
Figure 5 Hierarchical cluster analysis (HCA) of 54 mouse
miRNAs in 6 mouse organs. The female mice received 5 daily
doses of 125 mg/kg b.wt/day of BaP by oral gavage. 6 organs were
unsupervised clustered with Pearson’s correlation analysis. The
results show tissue specific expression patterns (LU-lung, LI-liver, SP-
spleen, CO-colon, GS-glandular stomach, FS-forestomach).
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The analysis of the data from individual conditions
(dose and gender) by PCA and by HCA showed
that all datasets from a single organ usually grouped
together.
Specificity of gene expression changes induced in tissues
or cell lines has been reported previously. For example,
brain, lung, liver and spleen each displayed a unique altered
transcriptional signature in responding to infection [29].
Organ-specific gene expression profiles were found in
C57BL/6 mice after low dose radiation, with the genes
altered in spleen especially different from other organs [30].
We found that patterns from spleen and lung (target
organs) were the most distinct. In human studies, Shyam-
sundar et al. [31] found tissue-specific expression patterns
when comparing 35 human tumour tissues to their normal
tissues. Other evidence for human tumour tissue gene ex-
pression specificity includes data presented for brain,
breast, colon, endometrium, kidney, liver, lung, ovary, pros-
tate, skin and thyroid cancers [32-34].Target organs versus non-target organs
Variations in the genes induced in target and non-target
organs after carcinogen exposures have been reported,
between kidney (target) and liver (non-target) following
treatment of rats and mice with aristolochic acid [5,9] or
of rats with ochratoxin A [6], and between lung (target)
and liver (non-target) of mice treated with BaP [7].
However, because only a single target and non-target
organ were examined in these studies, it is possible that
differences in the genes induced in the two tissues may
represent organ-specific changes unrelated to carcino-
genesis. The current study has addressed this limitation
by comparing three target and three non-target organs.
Hundred of genes were significantly modulated by BaP
in each organ and the PCA results revealed that the
overall gene expression profile in the target organ group
differed from those regulated in the non-target organ
group. Interestingly, two target organs (lung and spleen)
presented strong variations from the three non-target
organs while another target organ, forestomach, was
closer to the non-target organs. HCA confirmed this re-
sult. This finding is very close to another PCA result
based on the expression data using oligonucleotide mi-
croarrays to capture splicing information of 22 mouse
tissues [35], which showed clearly that the lung and
spleen profiles were distinct from those of liver, colon
and stomach. Additionally, Taqman results confirmed
that several genes were modulated by BaP in a very simi-
lar pattern in lung and spleen, but different from the
other four organs. p53 signalling pathway genes Trp53
and Pcna were down-regulated, oncogene Src was up-
regulated. Tnfα and Nfκb were down-regulated in lung
and not changed in spleen. Trp53 is one of the most
studied tumour suppressor genes because its mutation
or function loss has been reported in many human and
animal cancers [36-38]. Recently a subset of genes were
identified to show significantly different expression in
p53 wild-type (WT) cells relative to p53-null cells after
BPDE exposure in human colon carcinoma cells
(HCT116), and the loss of this tumour suppressor influ-
enced the metabolic activation of BaP [39].
However, forestomach (target) has an overall profile
similar to that of the non-target organs, glandular stomach
and colon. One possible reason is that the crucial gene ex-
pression changes in forestomach were very few constitut-
ing a low percentage of the total variances, for example,
single gene deletion in forestomach tumourigenesis such
as Wwox [40] and c-H-Ras [41]. Another possible reason
is that the overall cell types between forestomach and
glandular stomach are similar and the variations due to
BaP treatment were not greater than the variations due to
cell similarity.
Of the eight genes that were modulated significantly dif-
ferently between target and non-target tissues (Figure 4),
miRNA lung spleen forestomach liver colon glandular 
stomach
1 mmu-miR-140 0.45 1.54
2 mmu-miR-199b 0.35
3 mmu-miR-207 1.58 1.81 0.16 1.70 2.44
4 mmu-miR-290 1.50 2.03 1.50 3.40 1.86
5 mmu-miR-291a-3p 1.70 1.85
6 mmu-miR-291a-5p 1.55
7 mmu-miR-291b-5p 0.65 2.33 2.64 3.11 1.86
8 mmu-miR-292-3p 0.58
9 mmu-miR-292-5p 0.59 1.87 3.24 4.10 1.57
10 mmu-miR-298 2.55 2.27 5.81 1.86
11 mmu-miR-346 2.01 2.35 1.57 1.72
12 mmu-miR-351 1.63 7.24 2.15 1.95
13 mmu-miR-376b 1.95 1.86 2.27
14 mmu-miR-433-5p 0.63 0.53 0.57 1.85 3.57
15 mmu-miR-434-3p 1.70 0.65
16 mmu-miR-464 0.32
17 mmu-miR-483 1.84
18 mmu-miR-489 2.19 0.30 2.13
19 mmu-miR-503 1.52 2.02 1.65
20 mmu-miR-542-5p 1.79
21 mmu-miR-546 2.74 0.61 1.99
Figure 6 The 21 miRNAs significantly modulated in 6 female mouse organs. The mice received 5 daily doses of 125 mg/kg b.wt/day of BaP
by oral gavage. The numbers represent fold change in expression relative to control organs (red, up-regulated; green, down-regulated). The
deregulated miRNAs were filtered by relative expression ratios with fold-change cut-offs of 1.5 (t-test p < 0.05).
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Wnt/β-catenin signalling (Cdh1 – cadherin 1; Ctnnb1 – ca-
tenin; Apc – adenomatous polyposis coli). Cyp1a1 encodes
the isoform of cytochrome P450 (CYP) that is principally
responsible for BaP metabolism. Tubb5 encodes class V
Beta-tubulin, overexpression of which in mammalian cells
disrupts microtubule organisation and spindle assembly,
and blocks cell proliferation [42]. Cav encodes caveolae
protein 1 (caveolin), a scaffolding protein that links integrin
subunits to the tyrosine kinase FYN; it is a tumour suppres-
sor gene candidate and a negative regulator of the Ras-p42/
44 mitogen-activated kinase cascade. It can also facilitate
the transit of Tyr-phosphorylated Stat3 into the nucleus
[43] and integrin-mediated activation of PI3-K/Akt [44].
The over-expression of caveolin has been suggested as abiomarker in some human cancers [45,46]. There is also
evidence for the interaction of STAT3 with caveolin and
HSP90 in plasma membrane raft and cytosolic complex
[43]. Genes including Heat shock protein (Hsp) 70kD
(Hspc8, Hspa5) and Hsp 90kD (Hspca) interact with Stat3
by binding to each other and positively activating each
other; caveolin can assist in the binding procedure.
In non-target organs, Wnt/β-catenin signalling genes
Cdh1, Ctnnb1 and Apc were down-regulated in colon
and glandular stomach. Cdh1 was also down-regulated
in liver and was the only gene that shows mRNA
changes in all three non-target organs. E-cadherin is as-
sociated with invasion and metastasis of human cancers
[47,48] and can be regulated by the Wnt pathway. In un-
stimulated cells most β-catenin is associated with E-
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to mediate cell adhesion [49]. The Wnt/β-catenin signal-
ling pathway can be regulated during carcinogenesis
leading accumulation of β-catenin in the nucleus. This
result is difficult to interpret in the context of carcino-
genesis. The lack of change in expression of Cdh1 in tar-
get organs would allow regulation to continue normally.
However, since cell adhesion is decreased during car-
cinogenesis such down-regulation should not matter.
But the story may not be this simple, because abnormal
accumulation of β-catenin in both the cytoplasm and
nuclei has been reported in during cancer development
[50-53].
Although consistently up-regulated in five organs (not
lung), Stat3 was the only gene that exhibited a trend in
dose-dependent changes in expression levels in the
Taqman study based on RT-PCR analysis (Table 3).
Dose-dependent changes in expression were observed in
almost all exposure conditions in the organs. Stat3 is a
member of a family of six different transcription factors
that are closely linked with tumourigenesis. Activated
Stat3 has been shown to protect tumour cells from
apoptosis and promote cell proliferation by regulating
genes coding anti-apoptotic and proliferation-associated
proteins such as Bcl, Ccnd1 and c-Myc [54,55]. Growing
evidence suggests that Stat3 functions as an oncogene
and plays a critical role in transformation and tumour
progression. Stat3 may be activated by many growth fac-
tors and oncogenic kinases. These growth factors in-
clude EGF, TGF-α, IL-6 and hepatocyte growth factors.
Oncogenic kinases include Janus kinase family (JAK)
and Src [56]. Other reported factors include Cox2 [57],
Erbb2 [58], JAKs & MAPK signalling [59,60] and Itgb4
[61]. Erbb2, Itgb4 and Src were differentially expressed
in the 6 organs in this study.
Functional analyses
cDNA microarray experiments identified hundreds of
BaP-modulated genes in each of the six organs, and the
potential significance of BaP-induced genes was investi-
gated by the analyses of their involvement in particular
biological processes, in regulatory or metabolic signalling
pathways and in gene association networks.
GO analyses were consistent with the hypothesis that
organs share some basic responses to BaP [62,63]. Thus
genes involved in basic physiological activities including
cellular macromolecule metabolism and cellular physio-
logical process were modulated in most or all organs.
Comparing the biological processes between target and
non-target organs, it was found that very few changes
were common in the target or in the non-target organs,
examples being translation initiation and protein-RNA
complex assembly. These processes may warrant further
functional investigation, as many eukaryotic translationinitiation factors were significantly modulated by BaP in
lung (Eif4g2, Eif3c, Eif4g3, Eif5 Mtif2 and Eif1), in spleen
(Eif5a, Eif5, Eif4g2, Eif4e and Eif1) and in forestomach
(Eif3h, Eif5, Eif4e2, Mtif2 and Eif4e).
Processes identified mainly in target but also in non-
target organs are those associated with cell cycle activity
and cellular growth; or the response to external stimulus
involving response to stress, response to heat and re-
sponse to abiotic stimulus. Although these processes
were mainly modulated in two target organs or in two
non-target organs, individual cell cycle activities and re-
sponses to external stimulus are potential candidate cat-
egories for functions that might discern target organs
from non-target organs. Under conditions of stress such
as DNA damage, cell cycle controls many genes to carry
out functions including DNA repair and apoptosis that
repair the aberrant cells or cause cell death [64]. Carcin-
ogens may induce tumourigenesis partly by mediating
cell cycle malfunction. For instance, in MCF-7 cells BaP
induces over-expression of many cell cycle genes includ-
ing TP53 and CDKN1A [39]; arsenate induces thymus
atrophy mediated by cell cycle arrest by down-regulating
E2F and related genes [65]; 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) makes cell cycle changes in murine fetal
liver [66] and Rb loss abrogates cell cycle control and
genome integrity to promote liver tumourigenesis [67].
The observation that many cell cycle genes are modu-
lated significantly by BaP in two or more target organs
indicates that processes such as DNA replication, cell
cycle checkpoint and apoptosis may be activated to allow
repair or elimination of damaged cells.
The biological processes response to stress (GO:0006950)
and response to DNA damage stimulus (GO:0006974) were
mainly found in the target organs. These processes are
known to be linked to immune response [64] and it is well
established that BaP modulates immune response; it sup-
presses the plaque-forming cell (PFC) response in adult
male deer mice (Peromyscus maniculatus) [68]; it can accu-
mulate the IgE antibody in serum and IL-4, IL-10, IL-
12p70 and IFN-γ secreted by spleen cells in mice [69]; and
it has been found be an immune suppressor at high doses,
but an enhancer at low doses [70].
Over 90% of all pathways appeared in two or three or-
gans and many of the individual pathways could poten-
tially be linked to BaP carcinogenesis. It is also possible
that pathways common to all or most organs are linked
to tumourigenesis. MAPK signalling, for instance, is
linked to BaP carcinogenicity: BaP may induce cell cycle
arrest through activation of ERK/Cyclin D1 signalling
[71]; BaP perturbs ERK/P38 pathway, which causes a de-
crease in stability and phosphorylation of p53 and
down-regulation of NFκb activation [72]; and BaP acti-
vates MAPK signalling in mouse cl41 cells [73], in RAW
126.7 cells [74] and in A/J mice lung tumourigenesis
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MAPK signalling showed a strongly tissue-specific pro-
file except for a very few common genes like Hspa8.
The Wnt signalling pathway was also commonly acti-
vated by BaP in all organs. The genes, including Ccnd2,
Csnk1a1, Ppp2r1a, Rock1, Cul1 and Camk2b, were vari-
ably modulated. In another study BaP caused LEF1 NH
(2)-terminal mutation in K14DeltaNLef1 transgenic mice,
which inhibits Wnt signalling and prevents induction of
p53 in skin cancer [76]. In a study in which female mice
were treated with 7,12-dimethylbenz[a]anthracene, Wnt
signalling was up-regulated during mammary tumourigen-
esis [77].
The genes significantly modulated by BaP were analysed
with IPA to show their regulatory relationships. Most net-
work functions were related to cancer, cell cycle, protein
synthesis and cellular development, which existed in almost
all the organs. Interestingly some core genes showed organ-
specific patterns, e.g. Ap1, Sp1 and PI3k, but the majority of
core genes were involved in all organs, including Trp53,
NFκb, Tnfα, Fos, Stat3, Myc, Ifng and Erbb2. If such path-
ways are of critical importance it is possible that the control
of organ specificity of cancer development occurs at a dif-
ferent level with different pathways having different roles in
different organs. For example Cdkn2a is generally involved
in cell cycle control but can induce apoptosis in lung [78].miRNA expression
miRNAs are small non-coding RNAs of 20–22 nucleo-
tides, typically excised from 60–110 nucleotide foldback
RNA precursor structures [79-82]. They function at tran-
scriptional or post-transcriptional levels through imperfect
pairing with the target mRNA of protein-coding genes.
miRNAs are related to crucial biological processes includ-
ing development, differentiation, apoptosis and prolifera-
tion [80,81]. Disregulation of miRNA function is linked to
the development of a variety of cancers, including breast
cancer [83,84], B-cell leukaemia [85,86], lung cancer
[87,88] and pancreatic cancer [89]. miRNA expression
profiling appears in some instances to provide a better
classification of cancer than conventional expression
microarray studies [90,91].
A variety of strategies may be used for miRNA detection,
including a bead-based flow-cytometric approach [84],
quantitative RT-PCR and serial analysis of gene expression
(SAGE) [92]. In the present study oligonucleotide miRNA
microarray analysis was used to assess miRNAs expression
profiles. The purpose was to investigate whether alterations
in miRNA profile following PAH exposure provides a better
indicator of subsequent carcinogenic site-of-action than
analysis of overall gene expression profile.
When the profiles of altered expression of 54 miRNAs
for the 6 organs were analysed by hierarchical clustering,the profiles appeared to be tissue specific. Similar results
have been reported in other studies [84,92,93]; for ex-
ample, Liu et al. [94] reported that 245 miRNAs from
humans and mice display tissue-specific expression sig-
natures, and Babak et al. [91] found that more than half
of 78 detected miRNAs were expressed specifically in 17
adult mouse tissues.
An interesting finding was that the magnitudes of the ex-
pression differences in the deregulated miRNAs were mod-
est. The highest fold-changes were 5.8 for mmu-miR-298 in
colon (up-regulation) and 0.164 for mmu-miR-207 in forest-
omach (down-regulation). 60% of the changes were smaller
than 2-fold. A study in human breast cancer showed that
over 90% of changes were 2-fold or less in 29 deregulated
miRNAs [83]. Such small changes in human cancers are
thought to be significant [85,86]. The importance of small
changes can be explained if individual miRNAs target many
genes, and if the small changes can themselves significantly
regulate individual target genes [92]. It has been shown that
oncogenes and/or tumour suppressor genes may be dis-
rupted dramatically by modulating miRNAs in human can-
cers; for example, miR-16-1 and miR-15a negatively regulate
BCL2 production and miR-17-92 cooperates with c-Myc to
stimulate proliferation [95].
Only two miRNAs were modulated by more than 2-
fold in mouse liver in the present study (Figure 6). In an-
other study, in which male B6C3F1 mice received 3 daily
doses of 150 mg/kg b.wt BaP, the maximum fold change
in a liver miRNA detected by microarray analysis was
1.35, but there were no changes in liver miRNAs that
were statistically significant [96]. A similar study of
miRNA expression changes induced in mouse liver by
dibenz[a,h]anthracene found that most changes were
small (<1.2 fold) and that only one miRNA that showed
a dose-dependent increase [97]. Thus although miRNA
response to environmental mutagens in liver may be a
sensitive biomarker for liver carcinogens [98], it does
not appear to be very sensitive for BaP, for which liver is
a non-target organ in mice. Yauk and co-workers also
found that in mouse lung 13 miRNAs were significantly
modulated following 3 daily doses of 150 or 300 mg/kg
b.wt BaP [99], but none of these were present in the
microarray used in the present study (Figure 6).
The majority of miRNAs in this study were up-
regulated by BaP. In this respect it is interesting that
miRNA expression levels in tumour samples appears to
be globally lower than in normal tissues. For example,
129 of 217 measured mammalian miRNAs were down-
regulated in multiple human cancers [84]. Calin et al.
[92] believe that these global miRNA levels facilitate the
proliferation and transformation of cells via oncogenes
genes such as HRAS. On the other hand, miRNAs can
down-regulate gene expression during various critical
cell processes including as apoptosis, differentiation and
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[100]. The up-regulation of miRNAs in the 6 organs
may also be associated with the down-regulation of tar-
get genes.
mmu-miR-292-5p is predicted to target Erbb2 (miRBase
database, http://www.mirbase.org/index.shtml). mmu-miR-
292-5p was up-regulated in forestomach, colon and glandu-
lar stomach, and down-regulated in lung. This may explain
the deregulation of Erbb2 in these organs where Erbb2 was
down-regulated in forestomach, colon and glandular stom-
ach but up-regulated in lung (see Erbb2 expression in
Table 3). However, confirmation of the interactions of miR-
NAs and genes, such as mmu-miR-292-5p and Erbb2,
needs further supporting evidence, e.g. confirmation of the
modulation of mmu-miR-292-5p by BaP with RT-PCR,
identification of the mechanism of mmu-miR-292-5p bind-
ing to Erbb2, or RNA interference to knock-out miRNA
functions, as in the studies of miRNAs in carcinogenesis
[101].Conclusions
In an investigation of the early changes induced in mouse
organs exposed to a carcinogen, we determined whether
DNA adduct formation, mRNA or miRNA expression can
distinguish those mouse organs that are targets for BaP car-
cinogenesis (lung, spleen, forestomach) from three organs
that are non-targets (liver, colon, glandular stomach). BaP-
DNA adduct levels in mice did not distinguish target from
non-target organs. miRNA expression patterns were modu-
lated by BaP in a tissue-specific manner, and to a small ex-
tent. Gene expression profiles have provided a portrait of
the overall tissue-specific expressions of six organs. Two
target organs, lung and spleen, showed similar gene expres-
sion patterns which were different from the other four or-
gans. p53 and Stat3 activities may suggest the mechanism
that distinguishes these two organs. Conversely, there is lit-
tle to distinguish the responses of the forestomach (target)
from the glandular stomach (non-target). The modulation
of Cdh1, Ctnnb1 and Apc indicates Wnt/β-catenin activity
specificity in non-target organs. Bioinformatic approaches
suggest that cell cycle, immune response, MAPK signalling
and Wnt signalling play critical roles in BaP carcinogenicity.
Studies that describe carcinogen-induced gene expression
differences between a single target organ and a single non-
target organ should be treated with caution.Methods
Animal treatment
Based on published protocols [4], the regimens for BaP
treatment in this study are predicted to result in signifi-
cant tumourigenesis in the long-term.
All animal procedures were carried out under licence
from the UK Home Office in accordance with the Animals(Scientific Procedures) Act 1986, and with the approval of
the Local Ethics Committee (Institute of Cancer Research).
In Experiment 1, groups of 5 male or female Balb/c
mice (6 weeks old, ~25 g each) were administered daily
doses of 125 mg/kg b.wt/day BaP (96% purity, Sigma-
Aldrich, Poole, UK) (dissolved in 0.2 mL corn oil) by
oral gavage. Some groups received 5 doses on days 1–5
and were killed on day 8. Others received a further 5
doses on days 8–12 and were killed on day 15. Control
mice received corn oil only.
In Experiment 2, groups of 5 male or female Balb/c
mice were administered 5 daily doses of 125, 250 or
375 mg/kg b.wt/day BaP on days 1–5 and killed on day
6. Control mice received corn oil only.
Six organs (lung, spleen, forestomach, liver, colon and
glandular stomach) were collected from each mouse, snap-
frozen in liquid nitrogen and stored at −80°C until analysis.
32P-Postlabelling analysis
Genomic DNA from the organs of 3 mice per treatment
group in Experiment 1 was isolated by a standard
phenol-chloroform extraction method and DNA ad-
ducts were measured using the nuclease P1 enrichment
version of the 32P-postlabelling method as described
[10]. Briefly, DNA (4 μg) was digested with micrococcal
nuclease and calf spleen phosphodiesterase, then with nu-
clease P1 and
32P-labelled as reported. Solvents for 2-D
thin-layer chromatography (TLC) of 32P-labelled adducts
on polyethyleneimine-cellulose were as described [102].
TLC plates were scanned using a Packard Instant Imager
(Dowers Grove, IL, USA) and DNA adduct levels were
calculated from the adduct cpm and the specific activity of
[γ-32P]ATP and expressed as adducts per 108 nucleotides.
An external BPDE-DNA standard [103] was employed for
identification of adducts in experimental samples.
cDNA microarray
Total RNA from the 6 organs treated in Experiment 2 was
extracted by Trizol reagent (Invitrogen, Paisley, UK) and
purified by Qiagen RNeasy mini kit (Qiagen, Crawley, UK)
according to the manufacturer’s instructions. RNA was
quantified spectrophotometrically, and integrity was deter-
mined using a 2100 BioAnalyzer (Agilent Technologies,
South Queensferry, UK). RNA that had an rRNA 28S/18S
ratio >1.2 was used.
Total RNA (4 μg) was reverse transcribed into cDNA
and labelled with Cy5 dye (GE Healthcare, Chalfont St
Giles, UK) using the Invitrogen indirect cDNA labelling kit
protocol (Invitrogen) according to the manufacturer’s in-
structions. Four μg of universal mouse reference RNA
(UMRR) (Stratagene, La Jolla, CA, USA) was labelled with
Cy3 dye (GE Healthcare). After labelling, repetitive se-
quences within the cDNA samples were blocked with
10 μg mouse Cot-1 DNA (Invitrogen) to prevent non-
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labelled test and Cy3-labelled reference were co-hybridised
onto custom cDNA mouse microarrays containing 13,825
features (NIA 15 K Mouse cDNA clone set) [104]. Three
total RNA samples from 3 mice were hybridised with
UMRR. Slides were incubated at 42°C for 16 hours. Washes
were performed once in 2× SSC and 0.1% (w/v) SDS for
15 min, followed by three washes in 0.1 × SSC and 0.1%
(weight/vol) SDS for 10 min each, and two final washes in
0.1 × SSC for 2 min each, all at 65°C. Slides were spin dried
before scanning on an Axon 4000A laser scanner (Axon In-
struments, Union City, CA, USA) according to the manu-
facturer’s protocol.
Microarray data preparation
The initial quality analysis of the scanned slides was car-
ried out using GenePix Pro v-5.1 (Axon Instruments). A
spot was automatically flagged for inclusion if the signal
intensity of >75% of the pixels from either the Cy3 or
Cy5 channels was 1 S.D. above background intensity.
Spot quality was also assessed visually to fine tune the
flagging. Raw data from GenePix were imported into
GeneSpring v-7.2 (Agilent Technologies) without back-
ground subtraction and LOWESS normalisation [105]
was applied. Natural log transformed averaged Cy5/Cy3
ratios were used in all subsequent analyses. PCA and
HCA were performed on significantly modulated genes.
The gene expression data discussed in this publication
have been deposited in EMBL-EBI arrayExpress (https://
www.ebi.ac.uk/arrayexpress/) with accession number E-
MTAB-80.
Pathway analysis
All genes modulated significantly by BaP in each organ
were included for these analyses. Gene ontology (GO)
[106] was performed by Database for Annotation,
Visualization and Integrated Discovery (DAVID) [107].
In this study we concentrated on the significant (p <
0.05) biological processes. A second approach concen-
trated on gene interaction and cascade mechanisms like
signalling transduction. The signalling annotation from
pathway collections, including Biocarta, GenMAPP and
KEGG were carried out using Pathway Miner [108].
Thirdly, gene association network (GAN) analysis, which
examines all classes of relationships between genes, was
carried out using Ingenuity pathway analysis (IPA) (In-
genuity systems, Redwood City, CA, USA).
Taqman gene expression assay
cDNA was reversed transcribed from 1 μg total RNA (com-
prising equal amounts from 3 mice/group from Experiment
2) using random primers following the superscript III Re-
verse transcriptase first-strand cDNA synthesis protocol
(Invitrogen). The cDNA was diluted 1:10 to 200 μL and2 μL was used as template to perform Real-Time PCR in a
15-μl reaction. GAPDH was used as an endogenous control
(Applied Biosystems, Foster City, CA, USA) in multiplexed
PCR reactions on an ABI PRISM 7900HT Sequence Detec-
tion System (Applied Biosystems) with standard thermocy-
cling conditions (50°C for 2 min, 95°C for 10 min, then
40 cycles at 95°C for 15 s, 60°C for 1 min), using Taqman
Universal PCR Master Mix (Applied Biosystems). To con-
firm the modulated expression of the selected genes 20×
Assays-On-Demand™ gene expression primers and probes
(Applied Biosystems) were used.
The assay codes were: GAPDH-4352339E, Trp53-Mm
00441964_g1, Pcna-Mm00448100_g1, Ccng1-Mm00438
084_m1, Ephx1-Mm00468752_m1, Cyp1a1-Mm00487
218_m1, Cdh1-Mm00486906_m1, Ctnnb1-Mm0135039
4_m1, Apc-Mm00545877_m1, Stat3-Mm00456961_m1,
Erbb2-Mm00658541_m1, Src-Mm00436783_m1, Hspa
8-Mm01731394_gH, Hspa5-Mm00517691_m1, Fos-Mm
00487425_m1, Myc-Mm00487804_m1, NFκB-Mm00476
361_m1, Tnfα-Mm00443258_m1, Cav-Mm00483057_m
1, Tubb5-Mm00495804_m1, Cdkn2a-Mm00494449_m1,
Ccnd2-Mm00438071_m1.
PCR reactions were performed in triplicate and changes
in gene expression between the control (calibrator) and
treated samples after normalisation to the GAPDH refer-
ence were calculated using the comparative threshold
cycle (CT) method, where relative amount = 2-ΔΔCT and
ΔΔCT is the ΔCT of the target gene (threshold cycle test
gene - threshold cycle endogenous control) minus the
ΔCT of the calibrator sample (threshold cycle calibrator
gene - threshold cycle endogenous control).
MicroRNA
The 6 organs from 2 female BaP-treated (125 mg/kg/day
for 5 days) and 2 corn oil-treated mice from Experiment 2
were used for analysis of miRNA expression. Supernatants
containing total RNA, prepared as described above, were
transferred to columns in miracle miRNA isolation kit
(Stratagene, La Jolla, CA, USA) and miRNA isolated ac-
cording to the manufacturer’s instructions. Samples were
stored at −80°C until analysis.
The miRCURY LNA miRNA array (Exiqon, Vedback,
Denmark; kindly provided by Dr Eduardo Missiaglia, In-
stitute of Cancer Research; http://www.exiqon.com/array),
which contains 54 mouse miRNAs, was used: 0.1 μg
miRNA from BaP-treated mice was mixed with 8 μL 2.5×
labelling buffer, 1.4 μL Cy5 fluorescent dye, 0.7 μL positive
control, 14. μL labelling enzyme and the final volume ad-
justed to 20 μL with nuclease-free water. Another 0.1 μg
miRNA from corn oil-treated mice was mixed with the
same reagents, except for Cy3 instead of Cy5. Incubation
was at 0°C for 1 hour, then at 65°C for 15 min to stop the
labelling, after which the mixtures were concentrated to
7.5 μL and placed on ice.
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buffer (GE Healthcare, Amersham, UK) was added. The so-
lution was heated at 95°C for 3 min, centrifuged briefly,
then applied to the arrays on a heating block at 63°C for
5 min, then covered with a glass cover slip and incubated at
63°C for 24 hours in a hybridisation chamber. Then the ar-
rays were washed with solution A (20 mL 20x SSC, 4 mL
10% SDS, 176 mL HLPC-pure water) for less than 1 min at
60°C, followed by solution B (10 mL 20x SSC, 190 mL
HPLC-pure water) twice for 2 min at room temperature,
followed by solution C (2 mL 20x SSC, 198 mL HPLC-pure
water) for 2 min at room temperature, and finally briefly
with HPLC-pure water, then dried under a stream of air.
Scanning and image processing of the arrays was the same
as for cDNA microarrays. The data were loaded into Gene-
spring without background subtraction and normalised (per
spot method), and modulated miRNAs identified by the
fold-change method. Comparisons between the 6 organs
were performed in Microsoft Office Excel. The miRNA ex-
pression data have been deposited in EMBL-EBI arrayEx-
press (https://www.ebi.ac.uk/arrayexpress/) with accession
number E-MTAB-2407.
Statistical analysis
For DNA adducts, comparisons between males and females
and between 5-day and 10-day exposures were carried out
using Student’s t-test (2-tailed). DNA adduct levels in 6 or-
gans were tested by 1-way ANOVA and the Tukey-Kramer
Test was used to identify significant differences (p < 0.05)
between pairs of organs. For cDNA microarray data ana-
lyses, the significantly modulated genes were tested using
Welch’s t-tests between test and control samples with test
parameter non-adjusted p < 0.05. Two-way ANOVA was
used to test for significant differences between males and
females, as well as between the three levels of dosage with
BaP. For HCA, Pearson’s correlation was used to calculate
the distances with a Euclidean inter-group distance. For
gene functional analysis, Fisher’s exact test was applied in
gene ontology and pathway analyses. Pearson’s correlation
was employed in analysing expression relationships be-
tween microarray and Taqman assay results. For RT-PCR
data analyses, the differential expression was tested using
Welch’s t-test with the Benjamin-Hochberg multiple testing
correction. For the miRNA analyses, one-way ANOVA was
used to test for significant differences between treated and
control tissues.
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